Prevent Study: Eculizumab In Aqp4-Igg-Positive Nmosd

PREVENT study: eculizumab in AQP4-IgG-positive NMOSD

PREVENT study: eculizumab in patients with AQP4 immunoglobin G-positive NMOSD

Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD

Current diagnostic and treatment measures for AQP4-IgG-positive NMOSD

Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder

AJE Video Bytes

New agents under investigation to treat AQP4-positive NMOSD

Quanta: PREVENTing relapses of Aqp4-Ab NMO

BrainWaves Staff

Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder

Touch Medical Media

Sean Pittock, ECTRIMS 2022: Phase 3 CHAMPION-NMOSD trial results – Ravulizumab for AQP4-IgG NMOSD

Touch Medical Media

Chronic cognitive impairment improved after eculizumab initiation in cases of NMOSD

SAkura: long-term safety and efficacy of satralizumab for NMOSD

Predictors of early serologic diagnosis of AQ4-IgG positive NMOSD

2021 RNDS | A Treatment Option for NMOSD

SRNA

Bruce Cree, MD, PhD, MAS: The NMOSD Landscape After the Inebilizumab Approval

Diagnostic criteria for NMOSD with positive AQP4-IgG

Understanding the AQP4 Antibody

The Sumaira Foundation

Bruce Cree, MD, PhD, MAS: Insights from the N-MOmentum Study of Inebilizumab

Novel treatment strategies for NMOSD

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Neurology Journal

SOLIRIS® (eculizumab) Mechanism of Action for Neuromyelitis Optica Spectrum Disorder (NMOSD)